September 9, 2008

Advances in Biopharmaceutical Technology in China Report Now Available

Research and Markets ( has announced the addition of the "Advances in Biopharmaceutical Technology in China" report to their offering.

Every organization has a China strategy, though for many of us it is simply "ignore it." A great opportunity exists in working with China and implementing an effective company strategy. However, winning in Asia in the new millennium will require fundamental changes in partnerships between western and Asian companies. Every company faces the question "What should our China strategy be?" But to neglect China is to forego opportunities to gain efficiency in most of the things we are trying to do. China provides opportunities that allow us to do different things and not just do things differently.

This volume provides an overview of the biopharmaceutical industry, and the state of technology. It will help the reader understand general business practice in China, analyze business opportunities and in identifying potential partners for working in China. It provides a ready reference for all aspects of the world of biopharmaceuticals in China, including general understanding, detailed technical and business descriptions, and detailed information on all types of organizations involved in biopharmaceuticals in China, whether they be companies (state owned or privately owned), universities, or government institutions.

By the Numbers:

-- 46 Internationally Recognized Authors

-- 23 Peer-Reviewed Chapters

-- 900 Pages

-- 15 Translated Chapters and Case Studies

-- 19 Case Studies and China Briefs

-- 380 References

-- Over 2,000 Index Entries

-- Current Listing of over 2,000 Chinese Biopharmaceuticals and Diagnostics (database)

Key Topics Covered:

-- Introduction: A China Biopharmaceuticals Strategy

-- An Overview of Biopharmaceutical Developments in China

-- China's Healthcare System and the Demand for Biopharmaceutical Products

-- China Pharmaceuticals Market Situation 2006

-- Biopharmaceutical Strategy in China: An Analysis of Innovation, Financing Policies, Talent, and Strategic Considerations Through 2010 (11th 5-year Plan)

-- Biopharmaceuticals in China: A Market, Import/Export, and Financial Review

-- Pharmacy and Drug Administration in China

-- Regulatory Requirements Applicable to Clinical Trials in China

-- FDA Requirements Applicable to Testing and Manufacturing Pharmaceutical Products in China for the U. S. Market

-- Protection and Enforcement of Biopharmaceutical Intellectual Property Rights in China - A Rapidly Evolving System

-- Biopharmaceutical Industry Venture Capital Investment in Mainland China

-- Drug Discovery and Development Partnerships: Outsourcing and Partnering with China

-- Doing Business in China

-- Current Status and Future Prospect of Biogeneric Companies in China

-- Biopharmaceutical Products in China

-- Chinese Bioindustry Parks: Evolution and Growth

-- Organizations in China involved in Biopharmaceutical Research and Manufacturing

-- Life Science and Health Science Education in China

-- Biopharmaceutical Research Collaboration between Western and Chinese Life Science Organization: A Guide to Prospective Partnership

-- Industrial Technology Developments for Chinese Biopharmaceuticals

-- Therapeutic Proteins in China

-- Vaccines in China: Status of the Chinese Vaccine Industry

-- Biotechnology and Analytical Methods in the Modernization of Traditional Chinese Herbal Medicine

-- CHINA Briefs (Articles)

 Companies Mentioned:  - Arnold & Porter, LLP - Beijing BaiAo Pharmaceutical Co., Ltd. - Beijing WanTai Biological Product Co., Ltd. - Business Monitor International - CanBiotech - Chemical Industry Press (China) - Chiltern International - China National Center for Biotechnology Development - China National Development and Reform Commission, Chinese Academy of Macroeconomic Research - China National Development and Reform Commission, High-Tech Industry Department - China Pharmaceutical University, College of Life Science and Technology - Chinese Academy of Social Sciences (CASS), Institute of World Economics and Politics - Chinese Ministry of Science and Technology, National Advisory Committee for "863 High Technology Program" - Deacons Hong Kong - Fudan University, International Finance - MMD Pharmahe - Nanjing University, Department of Biochemistry - National Institutes of Health (NIH), Office of Technology Transfer - National Vaccine & Serum Institute - Perkins Coie LLP (Los Angeles) - Shandong University - Shanghai CITIC GuoJian Pharmaceutical Co., Ltd. - Shanghai Tongji University, Investment Research Institute - Shanghai Venture Capital Corporation - Shenzhen Neptunus Interlong Biotech Co., Ltd - Shenzhen ZYPH Intelligence Co., Ltd. - Sichuan University, West China School of Pharmacy - Strategic Manufacturing Worldwide, Inc. - TechNova Medical Services - Tsinghua University, School of Medicine - 3DBGlobal, Inc. 

For more information visit